Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.57 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | CNR1 | P21554 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.50 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6631803 | 0.83 | KCNH2 (0.58) | EPHX2MEN1KMT2AHDAC8HDAC6 | |
| SCHEMBL27516888 | 0.82 | MEP1B (0.51) | KMT2ARAB9ANPC1 | |
| SCHEMBL11279082 | 0.81 | HPGD (0.62) | EPHX2MEN1KMT2AHDAC8HDAC6 | |
| SCHEMBL868395 | 0.81 | MAPT (0.61) | MEN1KMT2AHDAC8HDAC6HPGD | |
| SCHEMBL23959500 | 0.80 | EPHX2 (0.58) | EPHX2MEN1KMT2AHDAC8HDAC6 | |
| SCHEMBL11034177 | 0.79 | HDAC8 (0.65) | EPHX2MEN1KMT2AHDAC8HDAC6 | |
| SCHEMBL320807 | 0.78 | HPGD (0.68) | EPHX2MEN1KMT2AHDAC8HDAC6 | |
| SCHEMBL11111266 | 0.78 | GAA (0.62) | MEN1KMT2AHDAC8HDAC6GAA | |
| SCHEMBL392625 | 0.78 | ALDH1A1 (0.82) | MEN1KMT2AHDAC8HDAC6GAA | |
| SCHEMBL1454495 | 0.78 | MEN1 (0.63) | EPHX2MEN1KMT2AHDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11602527-B2 | Methods of use of cyclopamine analogs | INFINITY PHARMACEUTICALS, INC. (US) | 2023-03-14 | — | — | US | disclosed |
| US-20210275508-A1 | METHODS OF USE OF CYCLOPAMINE ANALOGS | INFINITY PHARMACEUTICALS, INC. | 2021-09-09 | — | — | US | disclosed |
| US-11007181-B2 | Cyclopamine analogs | INFINITY PHARMACEUTICALS, INC. (US) | 2021-05-18 | — | — | US | disclosed |
| US-10821102-B2 | Methods of use of cyclopamine analogs | INFINITY PHARMACEUTICALS, INC. (US) | 2020-11-03 | — | — | US | disclosed |
| US-20200121658-A1 | CYCLOPAMINE ANALOGS | ROYALTY SECURITY, LLC | 2020-04-23 | — | — | US | disclosed |
| US-10406139-B2 | Cyclopamine analogs | INFINITY PHARMACEUTICALS, INC. (US) | 2019-09-10 | — | — | US | disclosed |
| US-10314827-B2 | Methods of use of cyclopamine analogs | INFINITY PHARMACEUTICALS, INC. (US) | 2019-06-11 | — | — | US | disclosed |
| US-20190000816-A1 | CYCLOPAMINE ANALOGS | ROYALTY SECURITY, LLC | 2019-01-03 | — | — | US | disclosed |
| US-20180338962-A1 | METHODS OF USE OF CYCLOPAMINE ANALOGS | ROYALTY SECURITY, LLC | 2018-11-29 | — | — | US | disclosed |
| US-9951083-B2 | Cyclopamine analogs | INFINITY PHARMACEUTICALS, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-20100286180-A1 | METHODS OF USE OF CYCLOPAMINE ANALOGS | INFINITY PHARMACEUTICALS, INC. (US) | 2010-11-11 | — | — | US | disclosed |
| US-7812164-B2 | steroidal alkaloids; for treatment of disorders mediated by hedgehog pathway such as cancer | INFINITY PHARMACEUTICALS, INC. (US) | 2010-10-12 | — | — | US | disclosed |
| EP-2101580-A2 | METHODS OF USE FOR CYCLOPAMINE ANALOGS | Infinity Discovery, Inc. (US) | 2009-09-23 | — | — | EP | disclosed |
| EP-2096917-A2 | CYCLOPAMINE ANALOGS | Infinity Discovery, Inc. (US) | 2009-09-09 | — | — | EP | disclosed |
| US-20090216022-A1 | CYCLOPAMINE ANALOGS | ROYALTY SECURITY, LLC | 2009-08-27 | — | — | US | disclosed |
| US-20090012109-A1 | CYCLOPAMINE ANALOGS | ROYALTY SECURITY, LLC | 2009-01-08 | — | — | US | disclosed |
| US-20080293754-A1 | CYCLOPAMINE ANALOGS | ROYALTY SECURITY, LLC | 2008-11-27 | — | — | US | disclosed |
| WO-2008083252-A2 | METHODS OF USE FOR CYCLOPAMINE ANALOGS | INFINITY DISCOVERY, INC. (US) | 2008-07-10 | — | — | WO | disclosed |
| WO-2008083248-A2 | CYCLOPAMINE ANALOGS | INFINITY DISCOVERY, INC. (US) | 2008-07-10 | — | — | WO | disclosed |
| WO-2008033460-A2 | TREATING PAIN, DIABETES, AND LIPID METABOLISM DISORDERS | SCHERING CORPORATION (US) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10821102-B2 | Methods of use of cyclopamine analogs | PDE6C, CRYAB, TUBB3 | EPHX2 148/4885MEN1 2245/4885KMT2A 3923/4885 |
| US-11007181-B2 | Cyclopamine analogs | PDE6C, GLI1, SHH | EPHX2 640/4885MEN1 1685/4885KMT2A 4039/4885 |
| US-20190000816-A1 | CYCLOPAMINE ANALOGS | PDE6C, GLI1, SHH | EPHX2 640/4885MEN1 1685/4885KMT2A 4039/4885 |
| US-10406139-B2 | Cyclopamine analogs | PDE6C, GLI1, SHH | EPHX2 640/4885MEN1 1685/4885KMT2A 4039/4885 |
| US-20090012109-A1 | CYCLOPAMINE ANALOGS | GLI1, PDE6C, SHH | EPHX2 695/4885MEN1 2155/4885KMT2A 3766/4885 |
| US-20090216022-A1 | CYCLOPAMINE ANALOGS | GLI1, PDE6C, SHH | EPHX2 695/4885MEN1 2155/4885KMT2A 3766/4885 |
| US-20210275508-A1 | METHODS OF USE OF CYCLOPAMINE ANALOGS | PDE6C, CRYAB, TUBB3 | EPHX2 148/4885MEN1 2245/4885KMT2A 3923/4885 |
| US-20200121658-A1 | CYCLOPAMINE ANALOGS | PDE6C, GLI1, SHH | EPHX2 640/4885MEN1 1685/4885KMT2A 4039/4885 |
| US-11602527-B2 | Methods of use of cyclopamine analogs | PDE6C, CRYAB, TUBB3 | EPHX2 148/4885MEN1 2245/4885KMT2A 3923/4885 |
| US-20180338962-A1 | METHODS OF USE OF CYCLOPAMINE ANALOGS | PDE6C, CRYAB, TUBB3 | EPHX2 148/4885MEN1 2245/4885KMT2A 3923/4885 |
| US-20100286180-A1 | METHODS OF USE OF CYCLOPAMINE ANALOGS | PDE6C, CRYAB, TUBB3 | EPHX2 148/4885MEN1 2245/4885KMT2A 3923/4885 |
| US-20080293754-A1 | CYCLOPAMINE ANALOGS | GLI1, PDE6C, SHH | EPHX2 695/4885MEN1 2155/4885KMT2A 3766/4885 |
| US-10314827-B2 | Methods of use of cyclopamine analogs | PDE6C, CRYAB, TUBB3 | EPHX2 148/4885MEN1 2245/4885KMT2A 3923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.